# Air Products & Chemicals, Inc.: overview

APD · NYSE · CIK 2969 · [Materials](/sectors/materials.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/apd.md) · [Financials](/companies/apd/financials.md) · [Filings](/companies/apd/filings.md) · [Insiders](/companies/apd/insiders.md)

Latest reported revenue: [$3.16bn](/filings/0000002969-26-000036.md) for Q3 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 30, 2026 (XBRL us-gaap:Revenues, accession 0000002969-26-000036).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,188 d](/filings/0000002969-25-000055.md) | [2,932](/filings/0000002969-26-000008.md) | [2,916](/filings/0000002969-26-000020.md) | [3,023](/filings/0000002969-26-000036.md) | [3,167 d](/filings/0000002969-25-000055.md) | [3,103](/filings/0000002969-26-000008.md) | [3,172](/filings/0000002969-26-000020.md) | [3,161](/filings/0000002969-26-000036.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [76.1% d](/filings/0000002969-25-000055.md) | [22.0%](/filings/0000002969-26-000008.md) | [(79.8%)](/filings/0000002969-26-000020.md) | [26.2%](/filings/0000002969-26-000036.md) | [0.5% d](/filings/0000002969-25-000055.md) | [23.7%](/filings/0000002969-26-000008.md) | [23.7%](/filings/0000002969-26-000020.md) | [(66.3%)](/filings/0000002969-26-000036.md) |
| Net margin | % | [61.2% d](/filings/0000002969-25-000055.md) | [21.1%](/filings/0000002969-26-000008.md) | [(59.3%)](/filings/0000002969-26-000020.md) | [23.6%](/filings/0000002969-26-000036.md) | [0.2% d](/filings/0000002969-25-000055.md) | [21.9%](/filings/0000002969-26-000008.md) | [22.4%](/filings/0000002969-26-000020.md) | [(45.6%)](/filings/0000002969-26-000036.md) |
| Diluted EPS | $ per share | not reported | [2.77](/filings/0000002969-26-000008.md) | [(7.77)](/filings/0000002969-26-000020.md) | [3.20](/filings/0000002969-26-000036.md) | not reported | [3.04](/filings/0000002969-26-000008.md) | [3.19](/filings/0000002969-26-000020.md) | [(6.47)](/filings/0000002969-26-000036.md) |
| Free cash flow | $m | [(1,118) d](/filings/0000002969-25-000055.md) | [(1,306)](/filings/0000002969-26-000008.md) | [(1,563) d](/filings/0000002969-26-000020.md) | [(640) d](/filings/0000002969-26-000036.md) | [(257) d](/filings/0000002969-25-000055.md) | [(351)](/filings/0000002969-26-000008.md) | [(3.9) d](/filings/0000002969-26-000020.md) | [310 d](/filings/0000002969-26-000036.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-09-30) | FY2022 (2022-09-30) | FY2023 (2023-09-30) | FY2024 (2024-09-30) | FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [10.3](/filings/0000002969-23-000047.md) | [12.7](/filings/0000002969-24-000056.md) | [12.6](/filings/0000002969-25-000055.md) | [12.1](/filings/0000002969-25-000055.md) | [12.0](/filings/0000002969-25-000055.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [22.1%](/filings/0000002969-23-000047.md) | [18.4%](/filings/0000002969-24-000056.md) | [19.8%](/filings/0000002969-25-000055.md) | [36.9%](/filings/0000002969-25-000055.md) | [(7.3%)](/filings/0000002969-25-000055.md) |
| Net margin | % | [20.3%](/filings/0000002969-23-000047.md) | [17.8%](/filings/0000002969-24-000056.md) | [18.3%](/filings/0000002969-25-000055.md) | [31.6%](/filings/0000002969-25-000055.md) | [(3.3%)](/filings/0000002969-25-000055.md) |
| Diluted EPS | $ per share | [9.43](/filings/0000002969-23-000047.md) | [10.14](/filings/0000002969-24-000056.md) | [10.33](/filings/0000002969-25-000055.md) | [17.18](/filings/0000002969-25-000055.md) | [(1.77)](/filings/0000002969-25-000055.md) |
| Free cash flow | $bn | [0.9](/filings/0000002969-23-000047.md) | [0.2](/filings/0000002969-24-000056.md) | [(1.4)](/filings/0000002969-25-000055.md) | [(3.2)](/filings/0000002969-25-000055.md) | [(3.8)](/filings/0000002969-25-000055.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/apd/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $5.37bn | 18,316,711 |  | Added +262,275 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.26bn | 14,540,399 |  | Added +73,083 |
| [STATE FARM MUTUAL AUTOMOBILE INSURANCE CO](/funds/315032.md) | 2026-06-30 | $3.47bn | 11,840,799 |  | Unchanged |
| [Capital Research Global Investors](/funds/1422848.md) | 2026-06-30 | $3.11bn | 10,602,157 |  | Added +191,647 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $3.01bn | 10,270,853 |  | Added +160,358 |
| [Capital International Investors](/funds/1562230.md) | 2026-06-30 | $2.80bn | 9,567,173 |  | Reduced −368,505 |
| [Dodge & Cox](/funds/200217.md) | 2026-06-30 | $2.75bn | 9,393,493 |  | Added +161,918 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $2.59bn | 8,848,570 |  | Added +3,137,491 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.47bn | 5,020,340 |  | Added +28,617 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $1.43bn | 5,253,985 |  | Reduced −795,275 |

## Recent filings

[All 2,098 filings](/companies/apd/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-07-30 | 13:31 ET | [10-Q](/filings/0000002969-26-000036.md) | Quarterly report, period 2026-06-30 | 0000002969-26-000036 |
| 2026-07-30 | 06:58 ET | [8-K](/filings/0000002969-26-000034.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000002969-26-000034 |
| 2026-06-30 | 08:08 ET | [8-K](/filings/0001193125-26-289427.md) | 2.06 Material impairments; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-289427 |
| 2026-04-30 | 11:07 ET | [10-Q](/filings/0000002969-26-000020.md) | Quarterly report, period 2026-03-31 | 0000002969-26-000020 |
| 2026-04-30 | 06:50 ET | [8-K](/filings/0000002969-26-000018.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000002969-26-000018 |
| 2026-01-30 | 16:20 ET | [10-Q](/filings/0000002969-26-000008.md) | Quarterly report, period 2025-12-31 | 0000002969-26-000008 |
| 2026-01-30 | 07:40 ET | [8-K](/filings/0000002969-26-000006.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000002969-26-000006 |
| 2026-01-29 | 16:16 ET | [8-K](/filings/0001193125-26-029381.md) | 5.07 Shareholder vote results | 0001193125-26-029381 |
| 2025-12-11 | 06:01 ET | [DEF 14A](/filings/0001308179-25-000643.md) | Proxy statement, period 2026-01-28 | 0001308179-25-000643 |
| 2025-11-25 | 16:18 ET | [8-K](/filings/0001193125-25-297255.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-297255 |

## Latest annual report

[Form 10-K for the fiscal year ended Sep 30, 2025](/filings/0000002969-25-000055.md), filed Nov 20, 2025.

## Forecast league

Q4 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/18f5c8d7-9964-4480-a9d9-545aaa25bf40)

## About the filer

- CIK: 2969
- Tickers: APD
- Exchange: NYSE
- SIC code: 2810 Industrial Inorganic Chemicals
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 13:38 ET. No prices; not investment advice.